The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Capital infusion to accelerate Earendil’s R&D platform
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Subscribe To Our Newsletter & Stay Updated
